Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Basset

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosisSurbhi Sidana, Paolo Milani, Moritz Binder, et al.
Blood|February 2, 2018
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, et al.
Hemasphere|February 18, 2026
Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patientsClaudia Bellofiore, Marco Basset, Mario Nuvolone, et al.
Journal of the American Heart Association|December 24, 2024
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, et al.
JACC. Cardiooncology|September 12, 2025
Diagnostic Performance of the New Free Light Chain Ratio in Systemic AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Claudia Bellofiore, et al.
Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Journal of the American Society of Nephrology : JASN|March 21, 2024
Development and Validation of Staging Systems for AA AmyloidosisMarco Basset, Stefan O Schönland, Laura Obici, et al.
Blood Cancer Journal|February 17, 2021
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosisGiovanni Palladini, Bruno Paiva, Ashutosh Wechalekar, et al.
American Journal of Hematology|August 23, 2022
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathiesPasquale Cascino, Alice Nevone, Maggie Piscitelli, et al.
Leukemia|May 24, 2022
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosisAlice Nevone, Maria Girelli, Silvia Mangiacavalli, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosisSurbhi Sidana, Paolo Milani, Moritz Binder, et al.
Blood|February 2, 2018
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosisEfstathios Kastritis, Ioannis Papassotiriou, Giampaolo Merlini, et al.
Hemasphere|February 18, 2026
Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patientsClaudia Bellofiore, Marco Basset, Mario Nuvolone, et al.
Journal of the American Heart Association|December 24, 2024
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Roberta Mussinelli, et al.
JACC. Cardiooncology|September 12, 2025
Diagnostic Performance of the New Free Light Chain Ratio in Systemic AmyloidosisPaolo Milani, Giuseppe Damiano Sanna, Claudia Bellofiore, et al.
Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
Journal of the American Society of Nephrology : JASN|March 21, 2024
Development and Validation of Staging Systems for AA AmyloidosisMarco Basset, Stefan O Schönland, Laura Obici, et al.
Blood Cancer Journal|February 17, 2021
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosisGiovanni Palladini, Bruno Paiva, Ashutosh Wechalekar, et al.
American Journal of Hematology|August 23, 2022
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathiesPasquale Cascino, Alice Nevone, Maggie Piscitelli, et al.
Leukemia|May 24, 2022
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosisAlice Nevone, Maria Girelli, Silvia Mangiacavalli, et al.
Pageof 6